PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $139 | -28.0% | 13,394 | -0.3% | 0.00% | – |
| Q2 2023 | $193 | +78.7% | 13,432 | -10.9% | 0.00% | – |
| Q1 2023 | $108 | -35.7% | 15,068 | +0.8% | 0.00% | – |
| Q4 2022 | $168 | -99.9% | 14,950 | +2.2% | 0.00% | – |
| Q3 2022 | $163,000 | +87.4% | 14,635 | +41.5% | 0.00% | – |
| Q2 2022 | $87,000 | -96.8% | 10,340 | -87.2% | 0.00% | – |
| Q4 2020 | $2,692,000 | -47.7% | 81,021 | -42.3% | 0.00% | -100.0% |
| Q3 2020 | $5,151,000 | -11.8% | 140,462 | -20.8% | 0.00% | 0.0% |
| Q2 2020 | $5,837,000 | – | 177,368 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
| Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
| Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
| Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
| Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
| Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
| StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
| MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
| NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |